Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2018
At a glance
- Drugs Ipilimumab (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- 19 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2019.
- 15 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 29 May 2015 Trial design presented at 51st Annual Meeting of the American Society of Clinical Oncology.